Shares of Masimo Co. (NASDAQ:MASI) have received an average recommendation of “Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $164.20.
MASI has been the subject of several research analyst reports. BTIG Research reiterated a “hold” rating on shares of Masimo in a research report on Thursday, August 1st. UBS Group lifted their price objective on Masimo from $172.00 to $180.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Stifel Nicolaus lifted their price objective on Masimo from $165.00 to $170.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Finally, BidaskClub downgraded Masimo from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 6th.
MASI traded up $0.13 during trading on Friday, reaching $151.63. The company had a trading volume of 5,517 shares, compared to its average volume of 318,725. The stock has a market cap of $8.19 billion, a P/E ratio of 50.08, a PEG ratio of 2.38 and a beta of 1.22. The business has a 50 day simple moving average of $152.01 and a 200-day simple moving average of $142.73. Masimo has a 52 week low of $98.23 and a 52 week high of $160.25.
In other news, EVP Yongsam Lee sold 2,371 shares of the business’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $145.90, for a total transaction of $345,928.90. Following the sale, the executive vice president now owns 74,301 shares in the company, valued at $10,840,515.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Joe E. Kiani sold 18,437 shares of the business’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $160.02, for a total value of $2,950,288.74. Following the sale, the chief executive officer now owns 157,678 shares in the company, valued at approximately $25,231,633.56. The disclosure for this sale can be found here. Insiders sold 209,062 shares of company stock worth $31,927,074 in the last quarter. 11.50% of the stock is owned by insiders.
Several hedge funds have recently modified their holdings of the company. Capital Investment Advisory Services LLC acquired a new position in Masimo in the second quarter valued at approximately $25,000. Financial Gravity Wealth Inc. acquired a new position in Masimo in the second quarter valued at approximately $31,000. Pearl River Capital LLC acquired a new position in Masimo in the second quarter valued at approximately $37,000. Private Capital Group LLC lifted its holdings in Masimo by 92.1% in the second quarter. Private Capital Group LLC now owns 340 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 163 shares during the period. Finally, FinTrust Capital Advisors LLC acquired a new position in shares of Masimo during the 1st quarter worth approximately $61,000. Institutional investors and hedge funds own 83.07% of the company’s stock.
Masimo Company Profile
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Featured Story: What is a Special Dividend?
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.